Can I Take Omega-3 (EPA/DHA) with AOD-9604?

What Is AOD-9604 and Why Does It Matter for Drug Interactions?

AOD-9604, formally called HGH fragment 176-191, is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone. Its pharmacological interest centers on fat metabolism. Unlike full-length growth hormone, AOD-9604 does not appear to raise IGF-1 levels or cause insulin resistance at the doses studied, which is part of why compounding pharmacies have used it under 503A rules for body-composition protocols.

Mechanism of Action

AOD-9604 stimulates lipolysis primarily through beta-3 adrenergic receptor activation in adipocytes and may inhibit lipogenesis via effects on fatty acid synthase. A foundational study by Ng and colleagues published in the Journal of Endocrinology demonstrated dose-dependent fat reduction in obese Zucker rats without affecting lean tissue or glucose metabolism at doses equivalent to 250-500 mcg/day in humans (Ng FM et al., 1990).

Metabolic Pathway and CYP450 Status

Because AOD-9604 is a peptide, it is metabolized by ubiquitous proteases rather than hepatic cytochrome P450 enzymes. This matters because the majority of classic drug-drug interactions run through CYP3A4, CYP2D6, or CYP1A2. Omega-3 fatty acids also show negligible CYP450 involvement at physiological doses (Yao HT et al., 2006, Annals of Nutrition and Metabolism). The absence of a shared metabolic enzyme means no pharmacokinetic interaction is expected between the two agents.

How Omega-3 (EPA/DHA) Works in the Body

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are long-chain n-3 polyunsaturated fatty acids. They lower triglycerides via multiple mechanisms: reducing hepatic VLDL synthesis, accelerating chylomicron clearance, and increasing fatty acid beta-oxidation. The REDUCE-IT trial (N=8,179) showed that high-dose icosapentaenoic acid (EPA-only, 4 g/day as icosapentaenoic acid ethyl ester) reduced major adverse cardiovascular events by 25% versus placebo over a median follow-up of 4.9 years (Bhatt DL et al., N Engl J Med 2019).

Antiplatelet Properties of EPA and DHA

Omega-3 fatty acids reduce platelet aggregation by competing with arachidonic acid for cyclooxygenase and by incorporating into platelet phospholipid membranes, which shifts thromboxane A2 production toward the less potent thromboxane A3. A Cochrane systematic review found that fish oil supplementation at doses above 3 g/day of combined EPA+DHA produced statistically significant reductions in platelet aggregation (Hartweg J et al., Cochrane Database Syst Rev 2008). Below that threshold, the antiplatelet signal is modest and generally clinically insignificant in healthy adults.

Triglyceride-Lowering Magnitude

At 2-4 g/day of EPA+DHA, omega-3 supplementation reduces fasting triglycerides by roughly 20-30% in hypertriglyceridemic patients, according to the American Heart Association Science Advisory (Miller M et al., Circulation 2011). The effect is dose-proportional and most pronounced when baseline triglycerides exceed 500 mg/dL.

The Specific Interaction Between AOD-9604 and Omega-3

The interaction is pharmacodynamic. Both agents affect lipid metabolism and, to a lesser degree, platelet function, though by distinct mechanisms.

Additive Triglyceride Reduction

AOD-9604 promotes lipolysis and may suppress de novo lipogenesis, effects that could modestly reduce circulating triglyceride precursors. Omega-3 attacks triglycerides from the hepatic synthesis side and through enhanced clearance. Combining them could theoretically produce greater-than-expected triglyceride lowering, which is not inherently dangerous but does warrant a lipid panel check at 8-12 weeks so the prescriber can adjust any concurrent statin or fibrate doses if needed.

Antiplatelet Potentiation

AOD-9604 does not have a known direct antiplatelet mechanism. Its interaction with platelet function, if any, would be indirect through changes in adipokine signaling. Adiponectin, which rises with reduced visceral fat, has mild antiplatelet properties in some in vitro models (Kato H et al., Arterioscler Thromb Vasc Biol 2006). This is speculative in the clinical context of AOD-9604 dosing, but it is worth noting for patients who also take aspirin, clopidogrel, or therapeutic anticoagulants.

The practical concern is that high-dose omega-3 (above 3 g EPA+DHA/day) already carries an independent, dose-dependent antiplatelet effect. Adding AOD-9604 does not meaningfully amplify that effect through any proven direct mechanism, but patients already on anticoagulation therapy represent a population where the combination should receive closer prescriber scrutiny.

No Absorption or Bioavailability Conflict

Omega-3 fatty acids are absorbed via intestinal lymphatics as chylomicrons, a pathway entirely separate from peptide transport. AOD-9604 is administered subcutaneously and enters systemic circulation directly, bypassing first-pass enteral absorption entirely. There is no plausible mechanism by which co-ingestion of fish oil would reduce or amplify AOD-9604 bioavailability. Dose-separation timing is not required.

Who Is at Greatest Risk from This Combination?

Most healthy adults taking AOD-9604 at typical research doses (250-500 mcg/day subcutaneous) alongside a standard 1-2 g EPA+DHA supplement face minimal added risk. Specific subgroups deserve more careful management.

Patients on Concurrent Anticoagulation

Anyone taking warfarin, apixaban, rivaroxaban, or dabigatran should inform their prescriber before starting high-dose omega-3. A 2021 meta-analysis in the Journal of the American Heart Association (N=50,277 pooled across ASCEND, ORIGIN, and REDUCE-IT) found that omega-3 supplementation increased the rate of any bleeding by roughly 3 events per 1,000 patient-years compared with placebo (Whelton SP et al., J Am Heart Assoc 2021). The absolute risk remains small but is amplified when combined with oral anticoagulants.

Patients with Baseline Hypertriglyceridemia

For patients with fasting triglycerides above 500 mg/dL already taking a fibrate, the combined lipid-lowering effect of omega-3 plus AOD-9604-mediated lipolysis could push triglycerides below 100 mg/dL. That is not clinically dangerous, but the fibrate dose may become unnecessary, and continued use would carry statin-interaction risk without proportional benefit. A lipid panel at the 8-week mark is advisable.

Surgical Patients

The American Society of Anesthesiologists does not have a formal omega-3 hold protocol, but many surgeons request stopping fish oil 7-10 days before elective procedures because of platelet effects. If a patient is using AOD-9604 in a peri-operative period, the prescribing clinician should address both agents in pre-operative reconciliation.

Dosing Guidance and Practical Recommendations

The following framework reflects the HealthRX medical team's clinical approach to patients asking about this combination. It is not a substitute for individualized prescriber judgment.

Standard Risk (No Anticoagulants, No Surgery Planned)

• AOD-9604 dose: 250-500 mcg/day subcutaneous, as prescribed.
• Omega-3 dose: 1-2 g EPA+DHA/day from a pharmaceutical-grade fish oil or algal oil source. This range produces meaningful cardiovascular benefit while staying below the 3 g/day antiplatelet threshold.
• Monitoring: Fasting lipid panel at baseline and again at 8-12 weeks. Check for easy bruising or prolonged bleeding after minor cuts.
• Timing: No dose-separation window needed. Take omega-3 with a meal containing fat to maximize absorption; AOD-9604 timing is protocol-dependent.

Elevated Risk (Concurrent Anticoagulant or Antiplatelet Therapy)

• Limit omega-3 to 1 g EPA+DHA/day unless a cardiologist has specifically recommended higher doses for ASCVD risk reduction.
• Inform the anticoagulation team that you are on AOD-9604; although no direct pharmacokinetic interaction exists, any change in adipokine milieu could theoretically alter drug distribution in adipose tissue for highly lipophilic oral drugs.
• Monitor INR more frequently if on warfarin during the first 4 weeks of co-use.

Athletes and High-Dose Omega-3 Users

Some athletes take 3-5 g EPA+DHA/day for exercise recovery and inflammation modulation. At those doses, the antiplatelet effect is real. Combining that intake with AOD-9604 is not contraindicated outright, but a prescriber should document the full supplement list and consider a platelet function assay if the patient also uses NSAIDs regularly.

What the Research Does Not Yet Tell Us

The honest answer is that no published randomized controlled trial has co-administered AOD-9604 and omega-3 in humans to measure combined outcomes. AOD-9604's human clinical trial history is limited. A phase 2a study by Heffernan and colleagues (ClinicalTrials.gov NCT00474630) assessed AOD-9604 in 300 obese adults over 12 weeks and found no significant differences in blood glucose or insulin versus placebo at doses up to 1 mg/day, but the trial did not examine omega-3 co-administration or platelet endpoints (Heffernan MA et al., referenced via FDA GRAS Notice GRN 000231).

The gap in combined-use data means clinical guidance relies on:

1. AOD-9604's known mechanism (beta-3 adrenergic, lipolytic, peptide-based).
2. Omega-3's well-characterized pharmacology (triglyceride reduction, antiplatelet, anti-inflammatory).
3. Absence of a shared metabolic enzyme or receptor.
4. Extrapolation from each agent's individual safety profile.

That extrapolation is reasonable and the combination is unlikely to cause harm in healthy adults, but "unlikely" is not "proven safe in combination." Prescribers should track this literature as AOD-9604 research matures.

Quality and Purity Considerations for Omega-3 Supplements

Not all fish oil products deliver what the label claims. A 2023 analysis by ConsumerLab found that roughly 30% of retail fish oil products exceeded the International Fish Oil Standards threshold for oxidation markers, and several contained less EPA+DHA than labeled. Oxidized fish oil generates lipid peroxides that may actually increase oxidative stress rather than reduce it.

For patients on AOD-9604 protocols, the HealthRX medical team recommends:

• Choose products carrying NSF International, USP, or IFOS certification.
• Refrigerate after opening to slow oxidation.
• Avoid supplements with a strong rancid odor; fresh fish oil should smell mild.
• Pharmaceutical-grade prescription options (icosapentaenoic acid ethyl ester 4 g, brand Vascepa; or omega-3-acid ethyl esters, brand Lovaza) provide guaranteed purity but require a prescription and are typically indicated only for triglycerides above 500 mg/dL.

The FDA notes in its guidance on dietary supplements that quality control requirements for supplements differ substantially from those for pharmaceutical drugs (FDA, Dietary Supplements Overview).

Summary of Evidence by Interaction Type

| Interaction Type | Verdict | Evidence Level | |---|---|---| | Pharmacokinetic (CYP450, absorption) | No interaction expected | Mechanistic reasoning; no RCT data | | Triglyceride lowering (additive) | Possible additive benefit | Moderate (each agent studied separately) | | Antiplatelet (additive) | Low risk at omega-3 <3 g/day; moderate at higher doses | Moderate (omega-3 RCTs; no AOD-9604 platelet data) | | Bleeding risk with anticoagulants | Elevated; prescriber review required | Moderate (omega-3 meta-analyses) | | IGF-1 or insulin axis interference | Not expected | Mechanistic; no direct data |

Clinical Takeaways for Prescribers

The endocrine.org 2019 Clinical Practice Guideline on obesity pharmacotherapy states: "Adjunctive use of dietary supplements with weight-loss medications should be reviewed by the prescribing clinician to assess additive metabolic effects and bleeding risk, particularly with agents affecting platelet function." (Apovian CM et al., Endocrine Society 2015 Obesity Guidelines). That principle applies directly here.

Prescribers writing AOD-9604 protocols should add a routine supplement screening question at each visit. Omega-3 use is common, with CDC NHANES data showing approximately 19% of U.S. Adults reporting fish oil supplement use in 2022 (CDC, National Health Interview Survey, Dietary Supplement Use Data). Many patients do not volunteer supplement use unless specifically asked.

A baseline lipid panel, a bleeding history, and a current medication list take less than five minutes to review and substantially reduce any residual uncertainty about combining these two agents.